학술논문
'학술논문'
에서 검색결과 7,002건 | 목록
1~10
Academic Journal
Zampieri, S.; Carraro, U.; Bersch, I.; Smeriglio, P.; Barbieri, E.; Ganassi, M.; Leeuwenburgh, C.; Rosati, R.; Gargiulo, P.; Pond, A.; Lee Sweeney, H.
In: European Journal of Translational Myology . (European Journal of Translational Myology, 2023, 33(4))
Academic Journal
Campagnolo, Marta; Weis, Luca; Sandre, Michele; Tushevski, Aleksandar; Russo, Francesco Paolo; Savarino, Edoardo; Carecchio, Miryam; Stocco, Elena; Macchi, Veronica; De Caro, Raffaele; Parchi, Piero; Bubacco, Luigi; Porzionato, Andrea; Antonini, Angelo; Emmi, Aron
In Neurobiology of Disease 1 October 2024 200
Conference
Avesani, Marco; Calderaro, Luca; Foletto, Giulio; Agnesi, Costantino; Picciariello, Francesco; Santagiustina, Francesco; Scriminich, Alessia; Stanco, Andrea; Vedovato, Francesco; Zahidy, Mujtaba; Vallone, Giuseppe; Villoresi, Paolo
2021 Optical Fiber Communications Conference and Exhibition (OFC) Optical Fiber Communications Conference and Exhibition (OFC), 2021. :1-3 Jun, 2021
Report
Avesani, Marco; Foletto, Giulio; Padovan, Matteo; Calderaro, Luca; Agnesi, Costantino; Bazzani, Elisa; Berra, Federico; Bertapelle, Tommaso; Picciariello, Francesco; Santagiustina, Francesco B. L.; Scalcon, Davide; Scriminich, Alessia; Stanco, Andrea; Vedovato, Francesco; Vallone, Giuseppe; Villoresi, Paolo
Journal of Lightwave Technology 40 (6), 1658 - 1663 (2022)
Review
Revue Philosophique de la France et de l'Étranger, 2020 Jan 01. 210(1), 101-103.
Report
Avesani, Marco; Calderaro, Luca; Foletto, Giulio; Agnesi, Costantino; Picciariello, Francesco; Santagiustina, Francesco; Scriminich, Alessia; Stanco, Andrea; Vedovato, Francesco; Zahidy, Mujtaba; Vallone, Giuseppe; Villoresi, Paolo
Optics Letters 46, 2848 (2021)
Academic Journal
In Digital Applications in Archaeology and Cultural Heritage March 2023 28
Report
Fondazione Policlinico Universitario Campus Bio-Medico; IRCCS National Neurological Institute 'C. Mondino' Foundation; Società italiana per lo studio delle Cefalee (SISC); Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Azienda Ospedaliero Universitaria Policlinico Modena; Euganea Health Unit, Padua, Italy; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania 'Luigi Vanvitelli'; Ospedale di Prato; Azienda Policlinico Umberto I; Auxologico San Luca, Milano; Asst Degli Spedali Civili Di Brescia
STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia (Studio STAR)
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26. Erratum In: Lancet. 2023 Sep 2;402(10404):774. doi: 10.1016/S0140-6736(23)01812-3. Lancet. 2023 Oct 14;402(10410):1328. doi: 10.1016/S0140-6736(23)02236-5.
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9. Erratum In: Lancet Neurol. 2020 Nov;19(11):e10. doi: 10.1016/S1474-4422(20)30350-1.
Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14.
Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezadal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Apr;23(4):382-392. doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26. Erratum In: Lancet. 2023 Sep 2;402(10404):774. doi: 10.1016/S0140-6736(23)01812-3. Lancet. 2023 Oct 14;402(10410):1328. doi: 10.1016/S0140-6736(23)02236-5.
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9. Erratum In: Lancet Neurol. 2020 Nov;19(11):e10. doi: 10.1016/S1474-4422(20)30350-1.
Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14.
Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezadal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Apr;23(4):382-392. doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13.
Report
Azienda Ospedaliero Universitaria Policlinico Modena; Società italiana per lo studio delle Cefalee (SISC); IRCCS National Neurological Institute 'C. Mondino' Foundation; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Euganea Health Unit, Padua, Italy; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania 'Luigi Vanvitelli'; Ospedale di Prato; Azienda Policlinico Umberto I; Auxologico San Luca, Milano; Asst Degli Spedali Civili Di Brescia; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.
Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA. 2021 Jun 15;325(23):2348-2356. doi: 10.1001/jama.2021.7665.
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5.
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019 Aug;39(9):1075-1085. doi: 10.1177/0333102419858355. Epub 2019 Jun 24.
Winner PK, McAllister P, Chakhava G, Ailani J, Ettrup A, Krog Josiassen M, Lindsten A, Mehta L, Cady R. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA. 2021 Jun 15;325(23):2348-2356. doi: 10.1001/jama.2021.7665.
Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5.
검색 결과 제한하기
제한된 항목
[검색어] Luca, Padua
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어